Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
38
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Dac Nadia | Chief Commercial Officer | 2 | $0 | $0 | 2019-10-22 |
| Campoy Carlos | Chief Financial Officer | 2 | $0 | $0 | 2019-10-22 |
| Lavelle Erin | Chief Operating Officer | 8 | $0 | $19.6K | 2019-10-22 |
| STRECK PAUL | Chief Medical Officer | 5 | $0 | $0 | 2019-10-22 |
| Bucher James B | Sr. VP & General Counsel | 21 | $0 | $26.3K | 2019-10-22 |
| Azelby Robert | President and CEO | 8 | $0 | $0 | 2019-10-22 |
| Hassler Randal | SVP, Pharmaceutical Ops | 18 | $0 | $24.1K | 2019-10-22 |
| Preston Heather | Director | 6 | $0 | $0 | 2019-10-22 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 136 | $0 | $6.92M | 2019-10-22 |
| Carter Paul Rutherford | Director | 10 | $0 | $0 | 2019-10-22 |
| Redmile Group, LLC | Director | 13 | $0 | $0 | 2019-10-22 |
| Cleveland Paul B | Interim President and CEO | 12 | $0 | $0 | 2019-10-22 |
| Montgomery Alan Bruce | Director | 18 | $30.0K | $0 | 2019-10-22 |
| H LUNDBECK A S | 10% Owner | 3 | $0 | $0 | 2019-10-22 |
| YARNO WENDY L | Director | 10 | $50.0K | $0 | 2019-10-22 |
| SIEGALL CLAY B | Director | 29 | $0 | $1.44M | 2019-10-22 |
| Green Jeremy | Director | 4 | $0 | $0 | 2019-06-30 |
| Benedict Larry | Sr. VP Finance | 28 | $0 | $2.01M | 2019-04-25 |
| Latham John A | Chief Scientific Officer | 126 | $0 | $9.55M | 2019-02-06 |
| Litton Mark James | Chief Business Officer | 63 | $0 | $5.53M | 2018-06-01 |
| PAKIANATHAN DEEPIKA | Director, 10% Owner | 12 | $3.50M | $0 | 2018-05-23 |
| Carter Eric G | Interim Chief Medical Officer | 1 | $0 | $0 | 2018-04-23 |
| Sandoval Elisabeth | Chief Commercial Officer | 4 | $0 | $0 | 2018-02-16 |
| Schatzman Randall C | President and CEO | 69 | $0 | $9.41M | 2018-02-16 |
| DOW STEPHEN M | Director, 10% Owner | 19 | $250.0K | $10.84M | 2017-07-18 |
| Whitaker Timothy M | Chief Medical Officer | 2 | $0 | $0 | 2017-01-27 |
| Bridger Gary | Director | 8 | $2.50M | $0 | 2015-10-31 |
| Sevin Rosen Fund IX L.P. | Other | 2 | $0 | $42.69M | 2015-08-31 |
| JAGGERS JOHN V | Other | 12 | $0 | $8.55M | 2015-08-15 |
| Sevin Rosen IX Affiliates Fund L.P. | Other | 11 | $0 | $8.55M | 2015-08-12 |
| STURIALE NICHOLAS G | 10% Owner | 8 | $0 | $0 | 2015-06-04 |
| BONDERMAN DAVID | 10% Owner | 3 | $0 | $0 | 2014-05-13 |
| H.I.G. Venture Partners II, L.P. | 10% Owner | 8 | $0 | $0 | 2014-05-13 |
| Ventures West 8 Limited Partnership | 10% Owner | 6 | $2.50M | $0 | 2014-05-13 |
| Davidson Aaron | Director | 8 | $0 | $0 | 2014-05-13 |
| Novo A/S | 10% Owner | 3 | $5.50M | $0 | 2014-05-13 |
| BOCHNOWSKI JAMES J | 10% Owner | 8 | $3.50M | $0 | 2014-05-13 |
| BAYLESS JON W | 10% Owner | 5 | $0 | $0 | 2014-05-13 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| H LUNDBECK A S | 10% Owner | J Other deriv | 2019-10-22 | 2019-10-24 | 0 | — | $0 | 0 | SEC↗ |
| H LUNDBECK A S | 10% Owner | J Other deriv | 2019-10-22 | 2019-10-24 | 0 | — | $0 | 0 | SEC↗ |
| Azelby Robert | President and CEO | D To issuer deriv | 2019-10-22 | 2019-10-24 | 150,000 | — | $0 | 0 | SEC↗ |
| Azelby Robert | President and CEO | D To issuer deriv | 2019-10-22 | 2019-10-24 | 15,000 | — | $0 | 0 | SEC↗ |
| Azelby Robert | President and CEO | D To issuer deriv | 2019-10-22 | 2019-10-24 | 1,000,000 | — | $0 | 0 | SEC↗ |
| Azelby Robert | President and CEO | D To issuer deriv | 2019-10-22 | 2019-10-24 | 505,000 | — | $0 | 0 | SEC↗ |
| Carter Paul Rutherford | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 15,000 | — | $0 | 0 | SEC↗ |
| Carter Paul Rutherford | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 30,000 | — | $0 | 0 | SEC↗ |
| Carter Paul Rutherford | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 15,000 | — | $0 | 0 | SEC↗ |
| Carter Paul Rutherford | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 15,000 | — | $0 | 0 | SEC↗ |
| Carter Paul Rutherford | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 22,500 | — | $0 | 0 | SEC↗ |
| Cleveland Paul B | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 22,500 | — | $0 | 0 | SEC↗ |
| Cleveland Paul B | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 100,000 | — | $0 | 0 | SEC↗ |
| Cleveland Paul B | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 17,300 | — | $0 | 0 | SEC↗ |
| Cleveland Paul B | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 12,700 | — | $0 | 0 | SEC↗ |
| Cleveland Paul B | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 15,000 | — | $0 | 0 | SEC↗ |
| Cleveland Paul B | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 15,000 | — | $0 | 0 | SEC↗ |
| Montgomery Alan Bruce | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 15,000 | — | $0 | 0 | SEC↗ |
| Montgomery Alan Bruce | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 6,363 | — | $0 | 0 | SEC↗ |
| Montgomery Alan Bruce | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 15,000 | — | $0 | 0 | SEC↗ |
| Montgomery Alan Bruce | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 6,350 | — | $0 | 0 | SEC↗ |
| Montgomery Alan Bruce | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 6,363 | — | $0 | 0 | SEC↗ |
| Montgomery Alan Bruce | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 6,363 | — | $0 | 0 | SEC↗ |
| Montgomery Alan Bruce | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 22,500 | — | $0 | 0 | SEC↗ |
| Montgomery Alan Bruce | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 15,000 | — | $0 | 0 | SEC↗ |
| Montgomery Alan Bruce | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 12,727 | — | $0 | 0 | SEC↗ |
| Preston Heather | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 15,000 | — | $0 | 0 | SEC↗ |
| Preston Heather | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 6,350 | — | $0 | 0 | SEC↗ |
| Preston Heather | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 15,000 | — | $0 | 0 | SEC↗ |
| SIEGALL CLAY B | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 6,363 | — | $0 | 0 | SEC↗ |
| SIEGALL CLAY B | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 6,363 | — | $0 | 0 | SEC↗ |
| SIEGALL CLAY B | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 6,363 | — | $0 | 0 | SEC↗ |
| SIEGALL CLAY B | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 6,363 | — | $0 | 0 | SEC↗ |
| SIEGALL CLAY B | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 6,363 | — | $0 | 0 | SEC↗ |
| SIEGALL CLAY B | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 6,350 | — | $0 | 0 | SEC↗ |
| SIEGALL CLAY B | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 22,500 | — | $0 | 0 | SEC↗ |
| SIEGALL CLAY B | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 15,000 | — | $0 | 0 | SEC↗ |
| SIEGALL CLAY B | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 15,000 | — | $0 | 0 | SEC↗ |
| SIEGALL CLAY B | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 15,000 | — | $0 | 0 | SEC↗ |
| YARNO WENDY L | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 22,500 | — | $0 | 0 | SEC↗ |
| YARNO WENDY L | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 15,000 | — | $0 | 0 | SEC↗ |
| YARNO WENDY L | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 15,000 | — | $0 | 0 | SEC↗ |
| YARNO WENDY L | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 30,000 | — | $0 | 0 | SEC↗ |
| Smith Jeffrey T L | Managing Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 100,000 | — | $0 | 0 | SEC↗ |
| Smith Jeffrey T L | Managing Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 50,000 | — | $0 | 0 | SEC↗ |
| Smith Jeffrey T L | Managing Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 60,000 | — | $0 | 0 | SEC↗ |
| Smith Jeffrey T L | Managing Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 100,000 | — | $0 | 0 | SEC↗ |
| Smith Jeffrey T L | Managing Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 85,000 | — | $0 | 0 | SEC↗ |
| Smith Jeffrey T L | Managing Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 50,000 | — | $0 | 0 | SEC↗ |
| Smith Jeffrey T L | Managing Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 35,000 | — | $0 | 0 | SEC↗ |
| Smith Jeffrey T L | Managing Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 13,636 | — | $0 | 0 | SEC↗ |
| Smith Jeffrey T L | Managing Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 13,636 | — | $0 | 0 | SEC↗ |
| Smith Jeffrey T L | Managing Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 31,818 | — | $0 | 0 | SEC↗ |
| Smith Jeffrey T L | Managing Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 17,271 | — | $0 | 0 | SEC↗ |
| Hassler Randal | EVP, Pharmaceutical Ops. | D To issuer deriv | 2019-10-22 | 2019-10-24 | 150,000 | — | $0 | 0 | SEC↗ |
| Hassler Randal | EVP, Pharmaceutical Ops. | D To issuer deriv | 2019-10-22 | 2019-10-24 | 80,000 | — | $0 | 0 | SEC↗ |
| Hassler Randal | EVP, Pharmaceutical Ops. | D To issuer deriv | 2019-10-22 | 2019-10-24 | 80,000 | — | $0 | 0 | SEC↗ |
| Hassler Randal | EVP, Pharmaceutical Ops. | D To issuer deriv | 2019-10-22 | 2019-10-24 | 30,000 | — | $0 | 0 | SEC↗ |
| Hassler Randal | EVP, Pharmaceutical Ops. | D To issuer deriv | 2019-10-22 | 2019-10-24 | 75,000 | — | $0 | 0 | SEC↗ |
| Hassler Randal | EVP, Pharmaceutical Ops. | D To issuer deriv | 2019-10-22 | 2019-10-24 | 60,000 | — | $0 | 0 | SEC↗ |
| Hassler Randal | EVP, Pharmaceutical Ops. | D To issuer deriv | 2019-10-22 | 2019-10-24 | 60,000 | — | $0 | 0 | SEC↗ |
| Bucher James B | EVP & General Counsel | D To issuer deriv | 2019-10-22 | 2019-10-24 | 95,000 | — | $0 | 0 | SEC↗ |
| Bucher James B | EVP & General Counsel | D To issuer deriv | 2019-10-22 | 2019-10-24 | 50,000 | — | $0 | 0 | SEC↗ |
| Bucher James B | EVP & General Counsel | D To issuer deriv | 2019-10-22 | 2019-10-24 | 35,000 | — | $0 | 0 | SEC↗ |
| Bucher James B | EVP & General Counsel | D To issuer deriv | 2019-10-22 | 2019-10-24 | 70,000 | — | $0 | 0 | SEC↗ |
| Bucher James B | EVP & General Counsel | D To issuer deriv | 2019-10-22 | 2019-10-24 | 70,000 | — | $0 | 0 | SEC↗ |
| Bucher James B | EVP & General Counsel | D To issuer deriv | 2019-10-22 | 2019-10-24 | 135,000 | — | $0 | 0 | SEC↗ |
| Lavelle Erin | Chief Operating Officer | D To issuer deriv | 2019-10-22 | 2019-10-24 | 150,000 | — | $0 | 0 | SEC↗ |
| Lavelle Erin | Chief Operating Officer | D To issuer deriv | 2019-10-22 | 2019-10-24 | 300,000 | — | $0 | 0 | SEC↗ |
| Redmile Group, LLC | Director | U Tender deriv | 2019-10-22 | 2019-10-24 | 20,243 | — | $0 | 0 | SEC↗ |
| Redmile Group, LLC | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 54,757 | — | $0 | 20,243 | SEC↗ |
| Redmile Group, LLC | Director | X Exercise deriv | 2019-10-22 | 2019-10-24 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Redmile Group, LLC | Director | X Exercise deriv | 2019-10-22 | 2019-10-24 | 75,000 | — | $0 | 0 | SEC↗ |
| Redmile Group, LLC | Director | J Other deriv | 2019-10-22 | 2019-10-24 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Redmile Group, LLC | Director | U Tender deriv | 2019-10-22 | 2019-10-24 | 779,776 | — | $0 | 0 | SEC↗ |
| Redmile Group, LLC | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 22,500 | — | $0 | 0 | SEC↗ |
| Redmile Group, LLC | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 15,000 | — | $0 | 0 | SEC↗ |
| Redmile Group, LLC | Director | D To issuer deriv | 2019-10-22 | 2019-10-24 | 30,000 | — | $0 | 0 | SEC↗ |
| Dac Nadia | Chief Commercial Officer | D To issuer deriv | 2019-10-22 | 2019-10-24 | 250,000 | — | $0 | 0 | SEC↗ |
| STRECK PAUL | Chief Medical Officer | D To issuer deriv | 2019-10-22 | 2019-10-24 | 250,000 | — | $0 | 0 | SEC↗ |
| Campoy Carlos | Chief Financial Officer | D To issuer deriv | 2019-10-22 | 2019-10-24 | 270,000 | — | $0 | 0 | SEC↗ |
| H LUNDBECK A S | 10% Owner | P Buy | 2019-10-22 | 2019-10-24 | 85,923,561 | — | $0 | 0 | SEC↗ |
| Montgomery Alan Bruce | Director | U Tender | 2019-10-22 | 2019-10-24 | 9,628 | $18.00 | $173.3K | 0 | SEC↗ |
| SIEGALL CLAY B | Director | U Tender | 2019-10-22 | 2019-10-24 | 31,714 | $18.00 | $570.9K | 0 | SEC↗ |
| YARNO WENDY L | Director | U Tender | 2019-10-22 | 2019-10-24 | 5,000 | $18.00 | $90.0K | 0 | SEC↗ |
| Smith Jeffrey T L | Managing Director | A Award | 2019-10-22 | 2019-10-24 | 16,230 | — | $0 | 21,502 | SEC↗ |
| Smith Jeffrey T L | Managing Director | D To issuer | 2019-10-22 | 2019-10-24 | 21,502 | $18.00 | $387.0K | 0 | SEC↗ |
| Hassler Randal | EVP, Pharmaceutical Ops. | A Award | 2019-10-22 | 2019-10-24 | 14,346 | — | $0 | 19,780 | SEC↗ |
| Hassler Randal | EVP, Pharmaceutical Ops. | D To issuer | 2019-10-22 | 2019-10-24 | 19,780 | $18.00 | $356.0K | 0 | SEC↗ |
| Bucher James B | EVP & General Counsel | U Tender | 2019-10-22 | 2019-10-24 | 27,677 | $18.00 | $498.2K | 0 | SEC↗ |
| Bucher James B | EVP & General Counsel | A Award | 2019-10-22 | 2019-10-24 | 15,619 | — | $0 | 27,677 | SEC↗ |
| Lavelle Erin | Chief Operating Officer | U Tender | 2019-10-22 | 2019-10-24 | 16,092 | $18.00 | $289.7K | 0 | SEC↗ |
| Lavelle Erin | Chief Operating Officer | A Award | 2019-10-22 | 2019-10-24 | 11,684 | — | $0 | 16,092 | SEC↗ |
| Redmile Group, LLC | Director | U Tender | 2019-10-22 | 2019-10-24 | 8,244,896 | — | $0 | 0 | SEC↗ |
| STRECK PAUL | Chief Medical Officer | D To issuer | 2019-10-22 | 2019-10-24 | 1,390 | $18.00 | $25.0K | 0 | SEC↗ |
| Bucher James B | EVP & General Counsel | A Award | 2019-10-11 | 2019-10-24 | 904 | $9.20 | $8.3K | 12,058 | SEC↗ |
| STRECK PAUL | Chief Medical Officer | A Award | 2019-10-11 | 2019-10-24 | 1,390 | $9.20 | $12.8K | 1,390 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise deriv | 2019-09-16 | 2019-09-18 | 10,001 | — | $0 | 17,271 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise deriv | 2019-09-16 | 2019-09-18 | 22,727 | — | $0 | 0 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise | 2019-09-16 | 2019-09-18 | 22,727 | $4.46 | $101.4K | 27,999 | SEC↗ |
| Smith Jeffrey T L | Managing Director | S Sale | 2019-09-16 | 2019-09-18 | 32,728 | $18.44 | $603.5K | 5,272 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise | 2019-09-16 | 2019-09-18 | 10,001 | $3.47 | $34.7K | 38,000 | SEC↗ |
| Green Jeremy | Director | A Award deriv | 2019-06-30 | 2019-07-01 | 19,023 | $2622315.59 | $49.88B | 779,776 | SEC↗ |
| Bucher James B | EVP & General Counsel | A Award | 2019-05-31 | 2019-10-24 | 1,345 | $9.20 | $12.4K | 11,154 | SEC↗ |
| Green Jeremy | Director | A Award deriv | 2019-05-23 | 2019-05-24 | 22,500 | — | $0 | 22,500 | SEC↗ |
| Cleveland Paul B | Director | A Award deriv | 2019-05-23 | 2019-05-28 | 22,500 | — | $0 | 22,500 | SEC↗ |
| Carter Paul Rutherford | Director | A Award deriv | 2019-05-23 | 2019-05-28 | 22,500 | — | $0 | 22,500 | SEC↗ |
| Montgomery Alan Bruce | Director | A Award deriv | 2019-05-23 | 2019-05-28 | 22,500 | — | $0 | 22,500 | SEC↗ |
| SIEGALL CLAY B | Director | A Award deriv | 2019-05-23 | 2019-05-28 | 22,500 | — | $0 | 22,500 | SEC↗ |
| YARNO WENDY L | Director | A Award deriv | 2019-05-23 | 2019-05-28 | 22,500 | — | $0 | 22,500 | SEC↗ |
| Bucher James B | EVP & General Counsel | S Sale | 2019-04-25 | 2019-04-25 | 1,897 | $13.85 | $26.3K | 9,809 | SEC↗ |
| Lavelle Erin | Chief Operating Officer | S Sale | 2019-04-25 | 2019-04-25 | 1,434 | $13.67 | $19.6K | 4,408 | SEC↗ |
| Smith Jeffrey T L | Managing Director | D To issuer | 2019-04-25 | 2019-04-25 | 4,847 | $13.73 | $66.5K | 5,272 | SEC↗ |
| Benedict Larry | EVP and PAO | S Sale | 2019-04-25 | 2019-04-25 | 1,734 | $13.65 | $23.7K | 39,728 | SEC↗ |
| Hassler Randal | EVP, Pharmaceutical Ops. | S Sale | 2019-04-25 | 2019-04-25 | 1,738 | $13.85 | $24.1K | 5,434 | SEC↗ |
| Azelby Robert | President and CEO | A Award deriv | 2019-04-23 | 2019-04-25 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Bucher James B | EVP & General Counsel | A Award | 2019-04-23 | 2019-04-25 | 7,810 | — | $0 | 11,706 | SEC↗ |
| Lavelle Erin | Chief Operating Officer | A Award | 2019-04-23 | 2019-04-25 | 5,842 | — | $0 | 5,842 | SEC↗ |
| Smith Jeffrey T L | Managing Director | A Award | 2019-04-23 | 2019-04-25 | 9,288 | — | $0 | 10,119 | SEC↗ |
| Benedict Larry | EVP and PAO | A Award | 2019-04-23 | 2019-04-25 | 7,055 | — | $0 | 41,462 | SEC↗ |
| Hassler Randal | EVP, Pharmaceutical Ops. | A Award | 2019-04-23 | 2019-04-25 | 7,172 | — | $0 | 7,172 | SEC↗ |
| Dac Nadia | Chief Commercial Officer | A Award deriv | 2019-04-08 | 2019-04-10 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Green Jeremy | 10% Owner | A Award | 2019-03-04 | 2019-03-06 | 1,739,130 | $11.50 | $20.00M | 8,244,896 | SEC↗ |
| Azelby Robert | President and CEO | A Award deriv | 2019-02-06 | 2019-02-08 | 505,000 | — | $0 | 505,000 | SEC↗ |
| Azelby Robert | President and CEO | A Award deriv | 2019-02-06 | 2019-02-08 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Benedict Larry | EVP and PAO | A Award deriv | 2019-02-06 | 2019-02-08 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Bucher James B | EVP & General Counsel | A Award deriv | 2019-02-06 | 2019-02-08 | 135,000 | — | $0 | 135,000 | SEC↗ |
| Hassler Randal | EVP, Pharmaceutical Ops. | A Award deriv | 2019-02-06 | 2019-02-08 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Latham John A | Chief Scientific Officer | A Award deriv | 2019-02-06 | 2019-02-08 | 160,000 | — | $0 | 160,000 | SEC↗ |
| Lavelle Erin | Chief Operating Officer | A Award deriv | 2019-02-06 | 2019-02-08 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Smith Jeffrey T L | Managing Director | A Award deriv | 2019-02-06 | 2019-02-08 | 100,000 | — | $0 | 100,000 | SEC↗ |
| STRECK PAUL | Chief Medical Officer | A Award deriv | 2019-01-21 | 2019-01-23 | 250,000 | — | $0 | 250,000 | SEC↗ |
| STRECK PAUL | Chief Medical Officer | A Award deriv | 2019-01-21 | 2019-02-01 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Redmile Group, LLC | Director | J Other deriv | 2018-12-31 | 2019-01-03 | 18,558 | $2558346.17 | $47.48B | 760,753 | SEC↗ |
| Campoy Carlos | Chief Financial Officer | A Award deriv | 2018-12-12 | 2018-12-14 | 270,000 | — | $0 | 270,000 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise deriv | 2018-12-03 | 2018-12-04 | 5,044 | — | $0 | 0 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise | 2018-12-03 | 2018-12-04 | 5,044 | $0.99 | $5.0K | 5,875 | SEC↗ |
| Smith Jeffrey T L | Managing Director | S Sale | 2018-12-03 | 2018-12-04 | 5,044 | $13.84 | $69.8K | 831 | SEC↗ |
| Benedict Larry | EVP and PAO | A Award | 2018-11-30 | 2019-02-08 | 954 | $9.35 | $8.9K | 34,407 | SEC↗ |
| Bucher James B | EVP & General Counsel | A Award | 2018-11-30 | 2019-02-08 | 273 | $9.35 | $2.6K | 3,896 | SEC↗ |
| Latham John A | Chief Scientific Officer | A Award | 2018-11-30 | 2019-02-08 | 487 | $9.35 | $4.6K | 244,180 | SEC↗ |
| Bucher James B | Sr. VP & General Counsel | A Award deriv | 2018-11-25 | 2018-11-27 | 70,000 | — | $0 | 70,000 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise deriv | 2018-11-01 | 2018-11-05 | 6,821 | — | $0 | 0 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise deriv | 2018-11-01 | 2018-11-05 | 18,181 | — | $0 | 0 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise deriv | 2018-11-01 | 2018-11-05 | 5,040 | — | $0 | 5,044 | SEC↗ |
| Latham John A | Chief Scientific Officer | S Sale | 2018-11-01 | 2018-11-05 | 1,319 | $13.78 | $18.2K | 243,693 | SEC↗ |
| Latham John A | Chief Scientific Officer | S Sale | 2018-11-01 | 2018-11-05 | 23,683 | $13.40 | $317.4K | 245,012 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise | 2018-11-01 | 2018-11-05 | 6,821 | $6.77 | $46.2K | 250,514 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise | 2018-11-01 | 2018-11-05 | 18,181 | $10.00 | $181.8K | 268,695 | SEC↗ |
| Smith Jeffrey T L | Managing Director | S Sale | 2018-11-01 | 2018-11-05 | 5,040 | $13.42 | $67.6K | 831 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise | 2018-11-01 | 2018-11-05 | 5,040 | $0.99 | $5.0K | 5,871 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise deriv | 2018-10-01 | 2018-10-03 | 18,185 | — | $0 | 0 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise deriv | 2018-10-01 | 2018-10-03 | 6,814 | — | $0 | 6,821 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise deriv | 2018-10-01 | 2018-10-03 | 5,040 | — | $0 | 10,084 | SEC↗ |
| Latham John A | Chief Scientific Officer | S Sale | 2018-10-01 | 2018-10-03 | 6,554 | $15.97 | $104.7K | 243,693 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise | 2018-10-01 | 2018-10-03 | 18,185 | $3.47 | $63.1K | 261,878 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise | 2018-10-01 | 2018-10-03 | 6,814 | $6.77 | $46.1K | 268,692 | SEC↗ |
| Latham John A | Chief Scientific Officer | S Sale | 2018-10-01 | 2018-10-03 | 18,445 | $15.25 | $281.3K | 250,247 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise | 2018-10-01 | 2018-10-03 | 5,040 | $0.99 | $5.0K | 5,871 | SEC↗ |
| Smith Jeffrey T L | Managing Director | S Sale | 2018-10-01 | 2018-10-03 | 2,000 | $15.97 | $31.9K | 831 | SEC↗ |
| Smith Jeffrey T L | Managing Director | S Sale | 2018-10-01 | 2018-10-03 | 3,040 | $15.26 | $46.4K | 2,831 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise deriv | 2018-09-04 | 2018-09-06 | 24,999 | — | $0 | 18,185 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise deriv | 2018-09-04 | 2018-09-06 | 5,040 | — | $0 | 15,124 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise | 2018-09-04 | 2018-09-06 | 24,999 | $3.47 | $86.7K | 268,692 | SEC↗ |
| Latham John A | Chief Scientific Officer | S Sale | 2018-09-04 | 2018-09-06 | 24,999 | $17.99 | $449.7K | 243,693 | SEC↗ |
| Smith Jeffrey T L | Managing Director | S Sale | 2018-09-04 | 2018-09-06 | 5,040 | $18.00 | $90.7K | 831 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise | 2018-09-04 | 2018-09-06 | 5,040 | $0.99 | $5.0K | 5,871 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise deriv | 2018-08-01 | 2018-08-02 | 24,999 | — | $0 | 43,184 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise deriv | 2018-08-01 | 2018-08-02 | 5,040 | — | $0 | 20,164 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise | 2018-08-01 | 2018-08-02 | 24,999 | $3.47 | $86.7K | 268,692 | SEC↗ |
| Latham John A | Chief Scientific Officer | S Sale | 2018-08-01 | 2018-08-02 | 24,999 | $19.55 | $488.7K | 243,693 | SEC↗ |
| Smith Jeffrey T L | Managing Director | S Sale | 2018-08-01 | 2018-08-02 | 4,060 | $19.49 | $79.1K | 1,811 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise | 2018-08-01 | 2018-08-02 | 5,040 | $0.99 | $5.0K | 5,871 | SEC↗ |
| Smith Jeffrey T L | Managing Director | S Sale | 2018-08-01 | 2018-08-02 | 980 | $19.76 | $19.4K | 831 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise deriv | 2018-07-02 | 2018-07-03 | 24,999 | — | $0 | 68,183 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise deriv | 2018-07-02 | 2018-07-03 | 5,040 | — | $0 | 25,204 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise deriv | 2018-07-02 | 2018-07-03 | 7,121 | — | $0 | 0 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise | 2018-07-02 | 2018-07-03 | 24,999 | $3.47 | $86.7K | 268,692 | SEC↗ |
| Latham John A | Chief Scientific Officer | S Sale | 2018-07-02 | 2018-07-03 | 24,999 | $15.48 | $387.0K | 243,693 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise | 2018-07-02 | 2018-07-03 | 7,121 | $1.65 | $11.7K | 7,952 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise | 2018-07-02 | 2018-07-03 | 5,040 | $0.99 | $5.0K | 12,992 | SEC↗ |
| Smith Jeffrey T L | Managing Director | S Sale | 2018-07-02 | 2018-07-03 | 12,161 | $15.49 | $188.4K | 831 | SEC↗ |
| Redmile Group, LLC | Director | J Other deriv | 2018-06-30 | 2018-07-18 | 16,927 | $2333332.21 | $39.50B | 742,195 | SEC↗ |
| Azelby Robert | President and CEO | A Award deriv | 2018-06-13 | 2018-06-15 | 1,000,000 | — | $0 | 1,000,000 | SEC↗ |
| Litton Mark James | Chief Business Officer | M Exercise deriv | 2018-06-01 | 2018-06-05 | 22,727 | — | $0 | 0 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise deriv | 2018-06-01 | 2018-06-05 | 5,040 | — | $0 | 30,244 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise deriv | 2018-06-01 | 2018-06-05 | 7,121 | — | $0 | 7,121 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise deriv | 2018-06-01 | 2018-06-05 | 2,272 | — | $0 | 93,182 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise deriv | 2018-06-01 | 2018-06-05 | 22,727 | — | $0 | 0 | SEC↗ |
| Litton Mark James | Chief Business Officer | S Sale | 2018-06-01 | 2018-06-05 | 4,474 | $18.24 | $81.6K | 102,189 | SEC↗ |
| Litton Mark James | Chief Business Officer | M Exercise | 2018-06-01 | 2018-06-05 | 22,727 | $0.99 | $22.5K | 124,916 | SEC↗ |
| Litton Mark James | Chief Business Officer | S Sale | 2018-06-01 | 2018-06-05 | 18,253 | $17.74 | $323.8K | 106,663 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise | 2018-06-01 | 2018-06-05 | 5,040 | $0.99 | $5.0K | 12,992 | SEC↗ |
| Smith Jeffrey T L | Managing Director | S Sale | 2018-06-01 | 2018-06-05 | 1,100 | $18.29 | $20.1K | 831 | SEC↗ |
| Smith Jeffrey T L | Managing Director | S Sale | 2018-06-01 | 2018-06-05 | 11,061 | $17.81 | $197.0K | 1,931 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise | 2018-06-01 | 2018-06-05 | 7,121 | $1.65 | $11.7K | 7,952 | SEC↗ |
| Latham John A | Chief Scientific Officer | S Sale | 2018-06-01 | 2018-06-05 | 20,200 | $17.76 | $358.8K | 248,492 | SEC↗ |
| Latham John A | Chief Scientific Officer | S Sale | 2018-06-01 | 2018-06-05 | 4,799 | $18.25 | $87.6K | 243,693 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise | 2018-06-01 | 2018-06-05 | 22,727 | $4.46 | $101.4K | 266,420 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise | 2018-06-01 | 2018-06-05 | 2,272 | $3.47 | $7.9K | 268,692 | SEC↗ |
| Benedict Larry | EVP and PAO | A Award | 2018-05-31 | 2019-02-08 | 1,319 | $9.35 | $12.3K | 33,453 | SEC↗ |
| Bucher James B | Sr. VP & General Counsel | A Award | 2018-05-31 | 2018-11-27 | 2,000 | $9.35 | $18.7K | 3,623 | SEC↗ |
| Redmile Group, LLC | Director | A Award deriv | 2018-05-23 | 2018-05-25 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Montgomery Alan Bruce | Director | A Award deriv | 2018-05-23 | 2018-05-25 | 15,000 | — | $0 | 15,000 | SEC↗ |
| PAKIANATHAN DEEPIKA | Director | A Award deriv | 2018-05-23 | 2018-05-25 | 15,000 | — | $0 | 15,000 | SEC↗ |
| SIEGALL CLAY B | Director | A Award deriv | 2018-05-23 | 2018-05-25 | 15,000 | — | $0 | 15,000 | SEC↗ |
| YARNO WENDY L | Director | A Award deriv | 2018-05-23 | 2018-05-25 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Carter Paul Rutherford | Director | A Award deriv | 2018-05-23 | 2018-05-25 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise deriv | 2018-05-16 | 2018-05-18 | 7,121 | — | $0 | 14,242 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise deriv | 2018-05-16 | 2018-05-18 | 5,040 | — | $0 | 35,284 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise | 2018-05-16 | 2018-05-18 | 5,040 | $0.99 | $5.0K | 5,871 | SEC↗ |
| Smith Jeffrey T L | Managing Director | M Exercise | 2018-05-16 | 2018-05-18 | 7,121 | $1.65 | $11.7K | 12,992 | SEC↗ |
| Smith Jeffrey T L | Managing Director | S Sale | 2018-05-16 | 2018-05-18 | 12,161 | $15.03 | $182.8K | 831 | SEC↗ |
| Green Jeremy | Director | A Award deriv | 2018-04-25 | 2018-04-26 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Carter Eric G | Interim Chief Medical Office | A Award deriv | 2018-04-23 | 2018-04-25 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Lavelle Erin | Chief Commercial Officer | A Award deriv | 2018-04-16 | 2018-04-18 | 300,000 | — | $0 | 300,000 | SEC↗ |
| Cleveland Paul B | Interim President and CEO | A Award deriv | 2018-03-26 | 2018-03-27 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Litton Mark James | Chief Business Officer | A Award deriv | 2018-02-16 | 2018-02-21 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Hassler Randal | EVP, Pharmaceutical Ops. | A Award deriv | 2018-02-16 | 2018-02-21 | 80,000 | — | $0 | 80,000 | SEC↗ |
| Smith Jeffrey T L | Managing Director | A Award deriv | 2018-02-16 | 2018-02-21 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Schatzman Randall C | President and CEO | A Award deriv | 2018-02-16 | 2018-02-21 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Latham John A | Chief Scientific Officer | A Award deriv | 2018-02-16 | 2018-02-21 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Sandoval Elisabeth | CCO & EVP, Corporate Strateg | A Award deriv | 2018-02-16 | 2018-02-21 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Benedict Larry | EVP and PAO | A Award deriv | 2018-02-16 | 2018-02-21 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Bucher James B | Sr. VP & General Counsel | A Award deriv | 2018-02-16 | 2018-02-21 | 70,000 | — | $0 | 70,000 | SEC↗ |
| Sandoval Elisabeth | Chief Commercial Officer | A Award deriv | 2017-12-20 | 2017-12-21 | 150,000 | — | $0 | 150,000 | SEC↗ |
| Hassler Randal | SVP, Pharmaceutical Ops | A Award deriv | 2017-12-14 | 2017-12-18 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Bucher James B | Sr. VP & General Counsel | A Award deriv | 2017-12-14 | 2017-12-18 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Latham John A | Chief Scientific Officer | A Award deriv | 2017-12-14 | 2017-12-18 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Smith Jeffrey T L | Sr. VP Translational Medicin | A Award deriv | 2017-12-14 | 2017-12-18 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Bucher James B | Sr. VP & General Counsel | A Award | 2017-11-30 | 2017-12-18 | 1,623 | $9.35 | $15.2K | 1,623 | SEC↗ |
| Latham John A | Chief Scientific Officer | A Award | 2017-11-30 | 2017-12-18 | 472 | $9.35 | $4.4K | 243,208 | SEC↗ |
| Litton Mark James | Chief Business Officer | M Exercise deriv | 2017-11-13 | 2017-11-15 | 16,519 | — | $0 | 0 | SEC↗ |
| Litton Mark James | Chief Business Officer | M Exercise | 2017-11-13 | 2017-11-15 | 16,519 | $1.65 | $27.3K | 116,451 | SEC↗ |
| Litton Mark James | Chief Business Officer | S Sale | 2017-11-13 | 2017-11-15 | 16,519 | $10.80 | $178.4K | 99,932 | SEC↗ |
| SIEGALL CLAY B | Director | M Exercise deriv | 2017-11-01 | 2017-11-03 | 9,090 | — | $0 | 0 | SEC↗ |
| SIEGALL CLAY B | Director | M Exercise deriv | 2017-11-01 | 2017-11-03 | 9,090 | — | $0 | 0 | SEC↗ |
| SIEGALL CLAY B | Director | M Exercise deriv | 2017-11-01 | 2017-11-03 | 9,090 | — | $0 | 0 | SEC↗ |
| SIEGALL CLAY B | Director | M Exercise | 2017-11-01 | 2017-11-03 | 9,090 | $1.65 | $15.0K | 22,624 | SEC↗ |
| SIEGALL CLAY B | Director | M Exercise | 2017-11-01 | 2017-11-03 | 9,090 | $0.99 | $9.0K | 31,714 | SEC↗ |
| SIEGALL CLAY B | Director | M Exercise | 2017-11-01 | 2017-11-03 | 9,090 | $1.27 | $11.5K | 13,534 | SEC↗ |
| Litton Mark James | Chief Business Officer | M Exercise deriv | 2017-10-16 | 2017-10-18 | 16,520 | — | $0 | 16,519 | SEC↗ |
| Litton Mark James | Chief Business Officer | S Sale | 2017-10-16 | 2017-10-18 | 16,520 | $12.33 | $203.7K | 99,932 | SEC↗ |
| Litton Mark James | Chief Business Officer | M Exercise | 2017-10-16 | 2017-10-18 | 16,520 | $1.65 | $27.3K | 116,452 | SEC↗ |
| DOW STEPHEN M | Director | P Buy | 2017-07-18 | 2017-07-18 | 25,000 | $10.00 | $250.0K | 307,190 | SEC↗ |
| YARNO WENDY L | Director | P Buy | 2017-07-18 | 2017-07-18 | 5,000 | $10.00 | $50.0K | 5,000 | SEC↗ |
| Smith Jeffrey T L | Sr. VP Translational Medicin | M Exercise deriv | 2017-06-20 | 2017-06-22 | 585 | — | $0 | 40,324 | SEC↗ |
| Smith Jeffrey T L | Sr. VP Translational Medicin | S Sale | 2017-06-20 | 2017-06-22 | 585 | $20.00 | $11.7K | 831 | SEC↗ |
| Smith Jeffrey T L | Sr. VP Translational Medicin | M Exercise | 2017-06-20 | 2017-06-22 | 585 | $0.99 | $579 | 1,416 | SEC↗ |
| Latham John A | Chief Scientific Officer | A Award | 2017-05-31 | 2017-12-18 | 333 | $13.09 | $4.4K | 242,736 | SEC↗ |
| Carter Paul Rutherford | Director | A Award deriv | 2017-05-24 | 2017-05-26 | 15,000 | — | $0 | 15,000 | SEC↗ |
| SIEGALL CLAY B | Director | A Award deriv | 2017-05-24 | 2017-05-26 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Cleveland Paul B | Director | A Award deriv | 2017-05-24 | 2017-05-26 | 15,000 | — | $0 | 15,000 | SEC↗ |
| YARNO WENDY L | Director | A Award deriv | 2017-05-24 | 2017-05-26 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Montgomery Alan Bruce | Director | A Award deriv | 2017-05-24 | 2017-05-26 | 15,000 | — | $0 | 15,000 | SEC↗ |
| DOW STEPHEN M | Director | A Award deriv | 2017-05-24 | 2017-05-26 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Preston Heather | Director | A Award deriv | 2017-05-24 | 2017-05-26 | 15,000 | — | $0 | 15,000 | SEC↗ |
| PAKIANATHAN DEEPIKA | Director, 10% Owner | A Award deriv | 2017-05-24 | 2017-05-26 | 15,000 | — | $0 | 15,000 | SEC↗ |
| YARNO WENDY L | Director | A Award deriv | 2017-04-11 | 2017-04-13 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Schatzman Randall C | President and CEO | M Exercise deriv | 2017-02-09 | 2017-02-13 | 30,000 | — | $0 | 78,181 | SEC↗ |
| Schatzman Randall C | President and CEO | S Sale | 2017-02-09 | 2017-02-13 | 30,000 | $25.03 | $750.9K | 115,172 | SEC↗ |
| Schatzman Randall C | President and CEO | M Exercise | 2017-02-09 | 2017-02-13 | 30,000 | $1.65 | $49.5K | 145,172 | SEC↗ |
| Litton Mark James | Chief Business Officer | A Award deriv | 2017-01-27 | 2017-01-31 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Schatzman Randall C | President and CEO | A Award deriv | 2017-01-27 | 2017-01-31 | 275,000 | — | $0 | 275,000 | SEC↗ |
| Smith Jeffrey T L | Sr. VP Translational Medicin | A Award deriv | 2017-01-27 | 2017-01-31 | 85,000 | — | $0 | 85,000 | SEC↗ |
| Sandoval Elisabeth | Chief Commercial Officer | A Award deriv | 2017-01-27 | 2017-01-31 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Latham John A | Chief Scientific Officer | A Award deriv | 2017-01-27 | 2017-01-31 | 95,000 | — | $0 | 95,000 | SEC↗ |
| Whitaker Timothy M | Chief Medical Officer | A Award deriv | 2017-01-27 | 2017-01-31 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Hassler Randal | SVP, Pharmaceutical Ops | A Award deriv | 2017-01-27 | 2017-01-31 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Benedict Larry | EVP and PAO | A Award deriv | 2017-01-27 | 2017-01-31 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Bucher James B | Sr. VP & General Counsel | A Award deriv | 2017-01-27 | 2017-01-31 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Litton Mark James | Chief Business Officer | M Exercise deriv | 2017-01-18 | 2017-01-20 | 1,498 | — | $0 | 33,039 | SEC↗ |
| Litton Mark James | Chief Business Officer | S Sale | 2017-01-18 | 2017-01-20 | 1,498 | $23.10 | $34.6K | 99,932 | SEC↗ |
| Litton Mark James | Chief Business Officer | M Exercise | 2017-01-18 | 2017-01-20 | 1,498 | $1.65 | $2.5K | 101,430 | SEC↗ |
| Litton Mark James | Chief Business Officer | M Exercise deriv | 2017-01-09 | 2017-01-09 | 500 | — | $0 | 34,537 | SEC↗ |
| Litton Mark James | Chief Business Officer | S Sale | 2017-01-09 | 2017-01-09 | 500 | $23.00 | $11.5K | 99,932 | SEC↗ |
| Litton Mark James | Chief Business Officer | M Exercise | 2017-01-09 | 2017-01-09 | 500 | $1.65 | $825 | 100,432 | SEC↗ |
| Litton Mark James | Chief Business Officer | M Exercise deriv | 2017-01-06 | 2017-01-09 | 1,326 | — | $0 | 35,037 | SEC↗ |
| Litton Mark James | Chief Business Officer | M Exercise deriv | 2017-01-06 | 2017-01-09 | 5,474 | — | $0 | 0 | SEC↗ |
| Litton Mark James | Chief Business Officer | S Sale | 2017-01-06 | 2017-01-09 | 6,800 | $23.02 | $156.5K | 99,932 | SEC↗ |
| Litton Mark James | Chief Business Officer | M Exercise | 2017-01-06 | 2017-01-09 | 1,326 | $1.65 | $2.2K | 106,732 | SEC↗ |
| Litton Mark James | Chief Business Officer | M Exercise | 2017-01-06 | 2017-01-09 | 5,474 | $1.27 | $7.0K | 105,406 | SEC↗ |
| Litton Mark James | Chief Business Officer | M Exercise deriv | 2017-01-05 | 2017-01-09 | 2,216 | — | $0 | 5,474 | SEC↗ |
| Litton Mark James | Chief Business Officer | S Sale | 2017-01-05 | 2017-01-09 | 2,216 | $23.00 | $51.0K | 99,932 | SEC↗ |
| Litton Mark James | Chief Business Officer | M Exercise | 2017-01-05 | 2017-01-09 | 2,216 | $1.27 | $2.8K | 102,148 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise deriv | 2016-12-01 | 2016-12-05 | 3,636 | — | $0 | 0 | SEC↗ |
| Smith Jeffrey T L | Sr. VP Translational Medicin | M Exercise deriv | 2016-12-01 | 2016-12-05 | 3,000 | — | $0 | 21,363 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise | 2016-12-01 | 2016-12-05 | 3,636 | $1.65 | $6.0K | 246,039 | SEC↗ |
| Latham John A | Chief Scientific Officer | S Sale | 2016-12-01 | 2016-12-05 | 3,136 | $22.64 | $71.0K | 242,903 | SEC↗ |
| Latham John A | Chief Scientific Officer | S Sale | 2016-12-01 | 2016-12-05 | 500 | $23.62 | $11.8K | 242,403 | SEC↗ |
| Smith Jeffrey T L | Sr. VP Translational Medicin | S Sale | 2016-12-01 | 2016-12-05 | 2,500 | $22.61 | $56.5K | 1,331 | SEC↗ |
| Smith Jeffrey T L | Sr. VP Translational Medicin | S Sale | 2016-12-01 | 2016-12-05 | 500 | $23.62 | $11.8K | 831 | SEC↗ |
| Smith Jeffrey T L | Sr. VP Translational Medicin | M Exercise | 2016-12-01 | 2016-12-05 | 3,000 | $1.65 | $5.0K | 3,831 | SEC↗ |
| Schatzman Randall C | President and CEO | A Award | 2016-11-30 | 2017-01-31 | 404 | $20.20 | $8.2K | 115,172 | SEC↗ |
| Benedict Larry | EVP and PAO | A Award | 2016-11-30 | 2017-01-31 | 742 | $20.20 | $15.0K | 30,989 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise deriv | 2016-11-09 | 2016-11-14 | 10,000 | — | $0 | 3,636 | SEC↗ |
| Latham John A | Chief Scientific Officer | M Exercise | 2016-11-09 | 2016-11-14 | 10,000 | $1.65 | $16.5K | 252,200 | SEC↗ |
| Latham John A | Chief Scientific Officer | S Sale | 2016-11-09 | 2016-11-14 | 10,000 | $30.18 | $301.8K | 242,200 | SEC↗ |
| Schatzman Randall C | President and CEO | M Exercise deriv | 2016-11-07 | 2016-11-09 | 10,000 | — | $0 | 108,181 | SEC↗ |
| Schatzman Randall C | President and CEO | S Sale | 2016-11-07 | 2016-11-09 | 10,000 | $25.16 | $251.6K | 114,768 | SEC↗ |